

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



WUXI APPTEC CO., LTD.*
無錫藥明康德新藥開發股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 2359)

ANNOUNCEMENT ON MAJOR OPERATING RESULTS
FROM JANUARY 2022 TO FEBRUARY 2022

This announcement is made by WuXi AppTec Co., Ltd.* (無錫藥明康德新藥開發股份有限公司) (the “**Company**”) pursuant to Rules 13.09(2)(a) and 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The Company is pleased to announce its major operating results from January 2022 to February 2022 as follows, for investors’ reference.

I. MAJOR OPERATING RESULTS FROM JANUARY 2022 TO FEBRUARY 2022

Since the beginning of the year 2022, the Company’s operating performance has been remarkable, and its unique and integrated CRDMO (Contract Research, Development and Manufacturing Organization) and CTDMO (Contract Testing, Development, Manufacturing Organization) business models have continued to exhibit strength. In particular, the year-over-year growth of both the order backlog and revenue of the Company from January 2022 to February 2022 have hit a historic high of over 65%. The Company expects that its year-over-year revenue growth for the first quarter of 2022 will reach 65% to 68%. Looking forward to the full year of 2022, the year-over-year revenue growth of the Company is expected to reach 65% to 70%.

II. EXPLANATORY MATTERS

The abovementioned major operating information of the Company from January 2022 to February 2022 serves only as a periodic explanation for investors' reference. The operating performance forecast set out in this announcement is made based on the current order backlog of the Company, and it has not been audited and does not constitute a profit forecast for the year of 2022. In addition, such operating performance forecast is subject to various prerequisites, including the continued stabilization or improvement of the COVID-19 global pandemic, the stable development of the global pharmaceutical industry and the stability of the international trade environment and regulatory environment of the countries where the main operations of the Company are located. Consequently, the realization of the operating performance forecast may be subject to certain risks as further particularized in the section headed "III. Risk Warnings" in the announcement on preliminary financial data for the year ended December 31, 2021 published by the Company on February 15, 2022.

Shareholders of the Company and investors should pay attention to the investment risks involved, and exercise caution when dealing in the securities of the Company.

By order of the Board
WuXi AppTec Co., Ltd.*
Dr. Ge Li
Chairman

Hong Kong, March 9, 2022

As of the date of this announcement, the board of the Company comprises Dr. Ge Li, Mr. Edward Hu, Dr. Steve Qing Yang, Mr. Zhaohui Zhang and Dr. Ning Zhao as executive Directors, Mr. Xiaomeng Tong and Dr. Yibing Wu as non-executive Directors and Dr. Jiangnan Cai, Ms. Yan Liu, Mr. Dai Feng, Dr. Hetong Lou and Mr. Xiaotong Zhang as independent non-executive Directors.

* *For identification purposes only*